In the United States, more than 32 million people suffer from unipolar depression, an indication that consists of major depressive disorder, minor depression, and dysthymia. Unipolar depression is associated with a high rate of drug treatment, which encompasses an extensive range of antidepressant treatments. However, poor patient response rates to treatment result in relatively individualized treatment patterns by both psychiatrists and primary care physicians (PCPs). This content examines psychiatrists’ and PCPs’ intricate treatment paradigms, as well as the motivations behind their prescribing decisions.


Related Reports

Unipolar Depression - Special Topics - Special Topics Comorbidities In Major Depressive Disorder US

Disorders such as anxiety, substance use disorder, and insomnia frequently coexist with major depressive disorder (MDD) and present tre...

View Details

Unipolar Depression - Landscape & Forecast - Disease Landscape & Forecast

The unipolar depression market is crowded and highly genericized. The prominent use of SSRIs and, to a lesser extent,

View Details

Unipolar Depression | Disease Landscape and Forecast | G7 | 2020

The unipolar depression market is crowded and highly genericized. The prominent use of SSRIs and, to a lesser extent, SNRIs as early-line treatments contributes to the challenges branded therapies...

View Details

Unipolar Depression - Unmet Need - Detailed, Expanded Analysis - Treatment-Resistant Depression (US & EU) - 2020

Numerous antidepressant therapies are available to treat major depressive disorder (MDD), many of which have long been generic and are entrenched in m...

View Details